Calithera Biosciences (NASDAQ:CALA) & Nabriva Therapeutics (NASDAQ:NBRV) Critical Analysis

Profitability

This table compares Nabriva Therapeutics and Calithera Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nabriva Therapeutics	-148.11%	-365.53%	-135.81%
Calithera Biosciences	N/A	N/A	N/A

Volatility & Risk

Nabriva Therapeutics has a beta of 1.53, meaning that its share price is 53% more volatile than the S&P 500. Comparatively, Calithera Biosciences has a beta of -3.14, meaning that its share price is 414% less volatile than the S&P 500.

Earnings and Valuation

This table compares Nabriva Therapeutics and Calithera Biosciences”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nabriva Therapeutics	$35.59 million	0.00	-$57.19 million	($19.20)	N/A
Calithera Biosciences	N/A	N/A	-$39.65 million	($2.01)	0.00

Calithera Biosciences has lower revenue, but higher earnings than Nabriva Therapeutics. Calithera Biosciences is trading at a lower price-to-earnings ratio than Nabriva Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

0.3% of Nabriva Therapeutics shares are owned by institutional investors. 1.6% of Nabriva Therapeutics shares are owned by insiders. Comparatively, 6.6% of Calithera Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Calithera Biosciences beats Nabriva Therapeutics on 7 of the 10 factors compared between the two stocks.

About Nabriva Therapeutics

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.

About Calithera Biosciences

Calithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.